Project Description

STATUS: Exited

In February of 2012, Cytomedix, Inc. (OTC/BB: CMXI), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced the completion of the acquisition of Aldagen, Inc., a privately held biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (“ALDHbr”) technology.

New Markets Team Member:

Mark Grovic